Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
This article was originally published in The Pink Sheet Daily
Executive Summary
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.
You may also be interested in...
Lilly Not Ducking M&A, But Will Play To Strengths In Cancer And Diabetes
The Indiana-based big pharma will focus on product-level acquisitions in its core areas of strengths now that it has rounded out its animal health business with its $5.4 billion acquisition of Novartis Animal Health.
Vedolizumab, Empagliflozin And Vintafolide Receive Positive EU Opinions After CHMP Meeting
The three new medicines tackle ulcerative colitis and Crohn’s disease, diabetes and ovarian cancer, respectively, with final approval from the European Commission expected in around two months.
AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.